title: Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.
abstract: Alternate erythropoietin (EPO)-mediated signaling via the heteromeric receptor composed of the EPO receptor and the β-common receptor (CD131) exerts the tissue-protective actions of EPO in various types of injuries. Herein we investigated the effects of the EPO derivative helix beta surface peptide (synonym: ARA290), which specifically triggers alternate EPO-mediated signaling, but does not bind the erythropoietic EPO receptor homodimer, on the progression of secondary tissue damage following cutaneous burns. For this purpose, a deep partial thickness cutaneous burn injury was applied on the back of mice, followed by systemic administration of vehicle or ARA290 at 1, 12, and 24 h postburn. With vehicle-only treatment, wounds exhibited secondary microvascular thrombosis within 24 h postburn, and subsequent necrosis of the surrounding tissue, thus converting to a full-thickness injury within 48 h. On the other hand, when ARA290 was systemically administered, patency of the microvasculature was maintained. Furthermore, ARA290 mitigated the innate inflammatory response, most notably tumor necrosis factor-alpha-mediated signaling. These findings correlated with long-term recovery of initially injured yet viable tissue components. In conclusion, ARA290 may be a promising therapeutic approach to prevent the conversion of partial- to full-thickness burn injuries. In a clinical setting, the decrease in burn depth and area would likely reduce the necessity for extensive surgical debridement as well as secondary wound closure by means of skin grafting. This use of ARA290 is consistent with its tissue-protective properties previously reported in other models of injury, such as myocardial infarction and hemorrhagic shock.
authors: Center for Engineering in Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
authors: Stefan
authors: S
authors: Bohr
authors: Suraj J
authors: SJ
authors: Patel
authors: Keyue
authors: K
authors: Shen
authors: Antonia G
authors: AG
authors: Vitalo
authors: Michael
authors: M
authors: Brines
authors: Anthony
authors: A
authors: Cerami
authors: Francois
authors: F
authors: Berthiaume
authors: Martin L
authors: ML
authors: Yarmush
mesh_terms: D000818:Animals; D002056:Burns / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002460:Cell Line; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D055806:Microvessels / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction / Q000187:drug effects*; D012867:Skin / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology; D013927:Thrombosis / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects
chemical_list: D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin
references: Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30
references: 18676614
references: Radiat Res. 1998 Aug;150(2):195-203
references: 9692365
references: Haematologica. 1999 Jun;84(6):541-7
references: 10366799
references: J Surg Res. 1998 Feb 1;74(2):131-40
references: 9587351
references: Int J Nanomedicine. 2012;7:1227-37
references: 22419870
references: J Burn Care Res. 2011 Mar-Apr;32(2):324-33
references: 21252689
references: J Burn Care Res. 2010 Mar-Apr;31(2):304-9
references: 20182376
references: Crit Care Med. 2006 Apr;34(4):1139-46
references: 16484928
references: Med Res Rev. 2013 May;33(3):637-64
references: 22430919
references: Mol Med. 2011 Mar-Apr;17(3-4):194-200
references: 21170473
references: Thromb Haemost. 1997 Dec;78(6):1505-9
references: 9423803
references: J Burn Care Res. 2012 Jan-Feb;33(1):136-46
references: 22138807
references: Biophys J. 1995 Jun;68(6):2608-14
references: 7647264
references: J Cell Sci. 1999 Jun;112 ( Pt 12):2049-57
references: 10341222
references: Eur J Neurosci. 2006 Feb;23(3):617-26
references: 16487143
references: J Cell Physiol. 2005 Feb;202(2):434-41
references: 15389590
references: Wound Repair Regen. 2013 Jan-Feb;21(1):35-43
references: 23110665
references: FEMS Immunol Med Microbiol. 2011 Jul;62(2):190-6
references: 21410562
references: Pharmacol Res. 2008 Aug;58(2):112-6
references: 18723091
references: Clin Plast Surg. 2009 Oct;36(4):617-25
references: 19793556
references: J Surg Res. 2010 Jan;158(1):112-20
references: 19394637
references: PLoS One. 2008;3(12):e3924
references: 19079544
references: Anesthesiology. 2011 Nov;115(5):1084-92
references: 21873879
references: J Crit Care. 2011 Aug;26(4):435.e1-7
references: 21036525
references: Curr Vasc Pharmacol. 2005 Jan;3(1):63-8
references: 15638783
references: J Invest Dermatol. 1991 Mar;96(3):323-7
references: 2002253
references: J Leukoc Biol. 2011 Mar;89(3):359-72
references: 21097697
references: Exp Cell Res. 2009 Feb 1;315(3):419-31
references: 19056379
references: Blood Cells Mol Dis. 2010 Jan 15;44(1):1-6
references: 19836979
references: Br J Surg. 2012 Sep;99(9):1295-303
references: 22829457
references: Tissue Eng Part A. 2011 Feb;17(3-4):429-37
references: 20807013
references: Mol Med. 2011 Sep-Oct;17(9-10):883-92
references: 21607291
references: Immunol Res. 1999;19(2-3):225-32
references: 10493176
references: Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6185-90
references: 18413601
references: Arch Dermatol Res. 2005 Jan;296(7):286-95
references: 15565301
references: J Cereb Blood Flow Metab. 2007 Mar;27(3):552-63
references: 16835629
references: Burns. 2010 May;36(3):397-402
references: 19765907
references: J Leukoc Biol. 1997 Oct;62(4):524-34
references: 9335324